Publications

1,743 patients across 56 transplant centers

Largest international real world kidney transplant study evaluating 
dd-cfDNA

Elevated AlloSure® detected rejection risk up to 4 months before biopsy

4x higher likelihood of detecting rejection on for-cause biopsies in patients with elevated AlloSure®

6x higher likelihood of detecting rejection on surveillance biopsies in patients with elevated AlloSure®

2,732 transplant patients across 67 transplants centers in United States since 2018

97.3% of patients monitored with HeartCare had normal graft function at 2 yrs

Patients monitored with HeartCare had a 94.9% survival rate at 2 years

Patients with AlloMap(+) AlloSure(+) are 6x more likely to have biopsy confirmed ACR compared to -/- result.

Patients with AlloMap(+) AlloSure(+) were ~2X more likely to experience poor outcomes, even in absence of histological rejection.

Landmark evidence supporting AlloSure® clinical utility

Early detection of active rejection before clinical symptoms

Reinforced confidence in molecular surveillance

Positive coverage decisions from major payers